Cargando…
Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial
BACKGROUND: There is no treatment for septic acute kidney injury (sAKI). The anti-inflammatory activity of prolonged-release pirfenidone (PR-PFD) could be beneficial in this clinical setting. METHODS: This study was a double-blind randomized clinical trial in sAKI patients with nephrology consultati...
Autores principales: | Chávez-Iñiguez, Jonathan S., Poo, Jorge L., Ibarra-Estrada, Miguel, García-Benavides, Leonel, Navarro-Blackaller, Guillermo, Cervantes-Sánchez, Cynthia, Nungaray-Pacheco, Eduardo, Medina-González, Ramón, Armendariz-Borunda, Juan, García-García, Guillermo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817311/ https://www.ncbi.nlm.nih.gov/pubmed/33520317 http://dx.doi.org/10.1155/2021/8833278 |
Ejemplares similares
-
The multifaceted role of pirfenidone and its novel targets
por: Macías-Barragán, José, et al.
Publicado: (2010) -
Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
por: Escutia-Gutiérrez, Rebeca, et al.
Publicado: (2021) -
Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study
por: Poo, Jorge Luis, et al.
Publicado: (2020) -
Probiotics in septic acute kidney injury, a double blind, randomized control trial
por: Chávez-Íñiguez, Jonathan S., et al.
Publicado: (2023) -
Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)